These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 16254306)
1. Commissioning for rare diseases: view from the frontline. Burls A; Austin D; Moore D BMJ; 2005 Oct; 331(7523):1019-21. PubMed ID: 16254306 [TBL] [Abstract][Full Text] [Related]
2. Limits on use of health economic assessments for rare diseases. Hyry HI; Stern AD; Cox TM; Roos JC QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281 [TBL] [Abstract][Full Text] [Related]
3. FDA program could boost treatments for neglected diseases. Traynor K Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098 [No Abstract] [Full Text] [Related]
4. The European rare diseases therapeutic initiative. Fischer A; Borensztein P; Roussel C PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832 [TBL] [Abstract][Full Text] [Related]
5. [Orphan drugs: availability, reliability and reimbursement]. Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041 [TBL] [Abstract][Full Text] [Related]
6. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives. John JE Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052 [No Abstract] [Full Text] [Related]
7. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Dear JW; Lilitkarntakul P; Webb DJ Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041 [TBL] [Abstract][Full Text] [Related]
8. Management of rare diseases. Walshe JM QJM; 2006 Feb; 99(2):123-4. PubMed ID: 16428334 [No Abstract] [Full Text] [Related]
10. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy. Roberts EA; Herder M; Hollis A CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953 [No Abstract] [Full Text] [Related]
11. Drugs for rare diseases: mixed assessment in Europe. Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539 [TBL] [Abstract][Full Text] [Related]
12. The many vs. the few. McCabe C Hastings Cent Rep; 2012; 42(5):6-7; author reply 8-9. PubMed ID: 23050291 [No Abstract] [Full Text] [Related]
13. The many vs. the few. Zallen DT Hastings Cent Rep; 2012; 42(5):4-5; author reply 8-9. PubMed ID: 22976402 [No Abstract] [Full Text] [Related]
14. Companies look for profit in orphan drugs. Thompson CA Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203 [No Abstract] [Full Text] [Related]
15. [Conference 1. An economic observatory for orphan drugs: myth or reality?]. Duguet C; Ferry A Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173 [No Abstract] [Full Text] [Related]
16. Reducing the cost of rare disease drugs. Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156 [No Abstract] [Full Text] [Related]
17. How should we model rare disease allocation decisions? London AJ Hastings Cent Rep; 2012; 42(1):3. PubMed ID: 22616383 [No Abstract] [Full Text] [Related]
18. Financing drug discovery for orphan diseases. Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746 [TBL] [Abstract][Full Text] [Related]
20. Drugs for exceptionally rare diseases: do they deserve special status for funding? Hughes DA; Tunnage B; Yeo ST QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]